Drug Delivery and Translational Research - Featured Articles: November 2022
Read the two equally voted for Best Papers for this issue!
Read Dr. Mandip Singh's featured article here. (this opens in a new tab)
Summary: A potent therapeutic option is sorely needed for triple negative breast cancer (TNBC) due to its clinical concerns, such as poor prognosis, drug resistance, and tumor recurrence. We here explored anti-cancer potential of synthetic cannabidiol (CBD; GLP grade) as a monotherapy or a chemosensitizer for doxorubicin (DOX) in TNBC (i.e., MDA-MB-231 and MDA-MB-468) cells. In comparison to 2D cultures, CBD showed greater IC50 values in hydrogel-based 3D cultures of MDA-MB-231 and MDA-MB-468 cells. Next-generation RNA sequencing revealed GADD45A, GADD45G, FASN, LOX, and integrin (i.e., -α5, -β5) genes to be novelly altered by CBD in MDA-MB-231 cells. CIM-16 plate-based migration assay and western blotting analysis disclosed that CBD induced anti-migratory effects in TNBC cells. Western blotting, RT-qPCR, and immunocytochemistry revealed that CBD inhibited autophagy of TNBC cells. CBD pre-treatment increased DOX sensitivity in TNBC cells. CBD pre-treatment accompanied by DOX treatment decreased LOX, integrin-α5, and increased caspase 9 respectively in MDA-MB-468 cells.
Read Dr. Maria José Alonso's featured article here. (this opens in a new tab)
Summary: The exact compositions of nanocarriers are rarely described in the literature. However, this information is critical for understanding and/or predicting the biological behaviors of the nanocarriers. This paper describes for the first time the exact composition of polymeric nanocapsules using liquid chromatography-mass spectrometry methodology and the results shows that actual composition is significantly different from the theoretical one. While the work focuses on polymeric nanocapsules, this methodology can be broadly applicable to other nanosystems and would be crucial for understating protein corona formation and targeting capability of functionalized nanocarriers.
Read the November 2022 issue here. (this opens in a new tab)